Daniela De Angelis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/775052/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet, The, 2022, 399, 1303-1312.	13.7	889
2	Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infectious Diseases, The, 2022, 22, 35-42.	9.1	612
3	The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction, 2011, 106, 1978-1988.	3.3	271
4	Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis. BMJ, The, 2021, 373, n1412.	6.0	114
5	HIV incidence in men who have sex with men in England and Wales 2001–10: a nationwide population study. Lancet Infectious Diseases, The, 2013, 13, 313-318.	9.1	100
6	A Markov model for HIV disease progression including the effect of HIV diagnosis and treatment: Application to AIDS prediction in England and Wales. , 1997, 16, 2191-2210.		90
7	<scp>HCV</scp> treatment rates and sustained viral response among people who inject drugs in seven <scp>UK</scp> sites: real world results and modelling of treatment impact. Journal of Viral Hepatitis, 2015, 22, 399-408.	2.0	86
8	Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis. European Journal of Public Health, 2012, 22, 187-192.	0.3	79
9	Estimating HIV Incidence, Time to Diagnosis, and the Undiagnosed HIV Epidemic Using Routine Surveillance Data. Epidemiology, 2015, 26, 653-660.	2.7	79
10	Hepatitis C virus treatment as prevention in people who inject drugs. Current Opinion in Infectious Diseases, 2015, 28, 576-582.	3.1	78
11	Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: Modelling the predicted impact of treatment under different scenarios. Journal of Hepatology, 2014, 61, 530-537.	3.7	76
12	Effect of pre-exposure prophylaxis and combination HIV prevention for men who have sex with men in the UK: a mathematical modelling study. Lancet HIV,the, 2016, 3, e94-e104.	4.7	68
13	Assessing the impact of national anti-HIV sexual health campaigns: trends in the transmission of HIV and other sexually transmitted infections in England. Sexually Transmitted Infections, 2001, 77, 242-247.	1.9	65
14	An evidence synthesis approach to estimating Hepatitis C Prevalence in England and Wales. Statistical Methods in Medical Research, 2009, 18, 361-379.	1.5	65
15	Estimates of Human Immunodeficiency Virus Prevalence and Proportion Diagnosed Based on Bayesian Multiparameter Synthesis of Surveillance Data. Journal of the Royal Statistical Society Series A: Statistics in Society, 2008, 171, 541-580.	1.1	64
16	Real-time nowcasting and forecasting of COVID-19 dynamics in England: the first wave. Philosophical Transactions of the Royal Society B: Biological Sciences, 2021, 376, 20200279.	4.0	62
17	Four key challenges in infectious disease modelling using data from multiple sources. Epidemics, 2015, 10, 83-87.	3.0	59
18	The burden of hepatitis C in England, lournal of Viral Hepatitis, 2007, 14, 570-576	2.0	57

2

#	Article	IF	CITATIONS
19	Estimating the prevalence of ex-injecting drug use in the population. Statistical Methods in Medical Research, 2009, 18, 381-395.	1.5	56
20	Hepatitis C Infection Among Injecting Drug Users in England and Wales (1992-2006): There and Back Again?. American Journal of Epidemiology, 2009, 170, 352-360.	3.4	50
21	Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM. Aids, 2015, 29, 1855-1862.	2.2	49
22	Bayesian back-calculation using a multi-state model with application to HIV. Statistics in Medicine, 2005, 24, 3991-4007.	1.6	45
23	Towards elimination of <scp>HIV</scp> transmission, <scp>AIDS</scp> and <scp>HIV</scp> â€related deaths in the <scp>UK</scp> . HIV Medicine, 2018, 19, 505-512.	2.2	45
24	Bayesian Emulation and Calibration of a Dynamic Epidemic Model for A/H1N1 Influenza. Journal of the American Statistical Association, 2014, 109, 1398-1411.	3.1	43
25	Defining populations and injecting parameters among people who inject drugs: Implications for the assessment of hepatitis C treatment programs. International Journal of Drug Policy, 2015, 26, 950-957.	3.3	42
26	Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. International Journal of Technology Assessment in Health Care, 2009, 25, 171-180.	0.5	41
27	New therapy explains the fall in AIDS incidence with a substantial rise in number of persons on treatment expected. Aids, 1999, 13, 103-108.	2.2	40
28	COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study. Scientific Reports, 2022, 12, .	3.3	39
29	Estimating hepatitis C prevalence in England and Wales by synthesizing evidence from multiple data sources. Assessing data conflict and model fit. Biostatistics, 2008, 9, 715-734.	1.5	38
30	Multiâ€state Markov models for disease progression in the presence of informative examination times: An application to hepatitis C. Statistics in Medicine, 2010, 29, 1161-1174.	1.6	37
31	New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England. Journal of Viral Hepatitis, 2016, 23, 631-643.	2.0	37
32	The UK's pandemic influenza research portfolio: a model for future research on emerging infections. Lancet Infectious Diseases, The, 2019, 19, e295-e300.	9.1	37
33	Analytical and Bootstrap Approximations to Estimator Distributions inL1Regression. Journal of the American Statistical Association, 1993, 88, 1310-1316.	3.1	36
34	Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management. Journal of Viral Hepatitis, 2008, 15, 271-278.	2.0	34
35	Monitoring the hepatitis C epidemic in England and evaluating intervention scaleâ€up using routinely collected data. Journal of Viral Hepatitis, 2019, 26, 541-551.	2.0	34
36	Conflict Diagnostics in Directed Acyclic Graphs, with Applications in Bayesian Evidence Synthesis. Statistical Science, 2013, 28, .	2.8	33

#	Article	IF	CITATIONS
37	Factors affecting repeated cessations of injecting drug use and relapses during the entire injecting career among the Edinburgh Addiction Cohort. Drug and Alcohol Dependence, 2015, 151, 76-83.	3.2	31
38	Bayesian evidence synthesis for a transmission dynamic model for HIV among men who have sex with men. Biostatistics, 2011, 12, 666-681.	1.5	30
39	Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) – a natural experiment (protocol). BMJ Open, 2019, 9, e029538.	1.9	30
40	MultiBUGS : A Parallel Implementation of the <i>BUGS</i> Modeling Framework for Faster Bayesian Inference. Journal of Statistical Software, 2020, 95, .	3.7	29
41	Estimating the Relative Incidence of Heroin Use: Application of a Method for Adjusting Observed Reports of First Visits to Specialized Drug Treatment Agencies. American Journal of Epidemiology, 2001, 153, 632-641.	3.4	27
42	Estimation of the rate of diagnosis of HIV infection in HIV infected individuals. Biometrika, 1994, 81, 287-294.	2.4	25
43	The Use of Human Immunodeficiency Virus Diagnosis Information in Monitoring the Acquired Immune Deficiency Syndrome Epidemic. Journal of the Royal Statistical Society Series A: Statistics in Society, 1994, 157, 3.	1.1	23
44	Estimating the number of people with hepatitis C virus who have ever injected drugs and have yet to be diagnosed: an evidence synthesis approach for Scotland. Addiction, 2015, 110, 1287-1300.	3.3	22
45	Mathematical models for the study of HIV spread and control amongst men who have sex with men. European Journal of Epidemiology, 2011, 26, 695-709.	5.7	21
46	Monitoring of the HIV Epidemic Using Routinely Collected Data: The Case of the United Kingdom. AIDS and Behavior, 2017, 21, 83-90.	2.7	21
47	Bayesian projection of the acquired immune deficiency syndrome epidemic. Journal of the Royal Statistical Society Series C: Applied Statistics, 2002, 47, 449-498.	1.0	20
48	Estimating the prevalence of problem drug use from drugâ€related mortality data. Addiction, 2020, 115, 2393-2404.	3.3	20
49	Elimination prospects of the Dutch HIV epidemic among men who have sex with men in the era of preexposure prophylaxis. Aids, 2018, 32, 2615-2623.	2.2	18
50	Evidence Synthesis for Stochastic Epidemic Models. Statistical Science, 2018, 33, 34-43.	2.8	17
51	Acquired Immune Deficiency Syndrome Predictions for England and Wales (1992-97): Sensitivity Analysis, Information, Decision. Journal of the Royal Statistical Society Series A: Statistics in Society, 1995, 158, 505.	1.1	16
52	Multiple parameter evidence synthesis—a potential solution for when information on drug use and harm is in conflict. Addiction, 2013, 108, 1529-1531.	3.3	16
53	Estimating age-stratified influenza-associated invasive pneumococcal disease in England: A time-series model based on population surveillance data. PLoS Medicine, 2019, 16, e1002829.	8.4	16
54	Applying prospective genomic surveillance to support investigation of hospital-onset COVID-19. Lancet Infectious Diseases, The, 2021, 21, 916-917.	9.1	14

#	Article	IF	CITATIONS
55	AIDS: the statistical basis for public health. Statistical Methods in Medical Research, 1993, 2, 75-91.	1.5	12
56	Reconstructing a spatially heterogeneous epidemic: Characterising the geographic spread of 2009 A/H1N1pdm infection in England. Scientific Reports, 2016, 6, 29004.	3.3	11
57	Tracking elimination of HIV transmission in men who have sex with men in England: a modelling study. Lancet HIV,the, 2021, 8, e440-e448.	4.7	11
58	Estimating time to onset of swine influenza symptoms after initial novel A(H1N1v) viral infection. Epidemiology and Infection, 2011, 139, 1418-1424.	2.1	10
59	Incidence of <i>Chlamydia trachomatis</i> infection in women in England: two methods of estimation. Epidemiology and Infection, 2014, 142, 562-576.	2.1	10
60	Estimation of HIV Burden through Bayesian Evidence Synthesis. Statistical Science, 2014, 29, .	2.8	10
61	A Bayesian multivariate factor analysis model for evaluating an intervention by using observational time series data on multiple outcomes. Journal of the Royal Statistical Society Series A: Statistics in Society, 2020, 183, 1437-1459.	1.1	10
62	Trends in undiagnosed HIV prevalence in England and implications for eliminating HIV transmission by 2030: an evidence synthesis model. Lancet Public Health, The, 2021, 6, e739-e751.	10.0	10
63	Impact of HIV on adult (15-54) mortality in London: 1979-96. Sexually Transmitted Infections, 1999, 75, 385-388.	1.9	9
64	Risk factors associated with severe hospital burden of COVID-19 disease in Regione Lombardia: a cohort study. BMC Infectious Diseases, 2021, 21, 1041.	2.9	9
65	Adjusting for time of infection or positive test when estimating the risk of a post-infection outcome in an epidemic. Statistical Methods in Medical Research, 2022, 31, 1942-1958.	1.5	9
66	Premature Mortality in Scottish Injecting Drug Users: A Life-history Approach. Scottish Medical Journal, 2012, 57, 38-42.	1.3	8
67	Quantifying Efficiency Gains of Innovative Designs of Two-Arm Vaccine Trials for COVID-19 Using an Epidemic Simulation Model. Statistics in Biopharmaceutical Research, 2022, 14, 33-41.	0.8	8
68	Efficient real-time monitoring of an emerging influenza pandemic: How feasible?. Annals of Applied Statistics, 2020, 14, 74-93.	1.1	8
69	Spatial mapping of hepatitis C prevalence in recent injecting drug users in contact with services. Epidemiology and Infection, 2012, 140, 1054-1063.	2.1	7
70	Forecasting the 2017/2018 seasonal influenza epidemic in England using multiple dynamic transmission models: a case study. BMC Public Health, 2020, 20, 486.	2.9	7
71	Real-time modelling of a pandemic influenza outbreak. Health Technology Assessment, 2017, 21, 1-118.	2.8	7
72	Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages. Journal of Infectious Diseases, 2022, 226, 808-811.	4.0	7

#	Article	IF	CITATIONS
73	A comparison of two frameworks for multi-state modelling, applied to outcomes after hospital admissions with COVID-19. Statistical Methods in Medical Research, 0, , 096228022211067.	1.5	7
74	Estimating Acquired Immune Deficiency Syndrome Incidence Accounting for Reporting Delay. Journal of the Royal Statistical Society Series A: Statistics in Society, 1994, 157, 31.	1.1	6
75	Bootstrapping unit root tests. Applied Economics, 1997, 29, 1155-1161.	2.2	6
76	Extending Bayesian back-calculation to estimate age and time specific HIV incidence. Lifetime Data Analysis, 2019, 25, 757-780.	0.9	6
77	Estimating Trends in Incidence, Time-to-Diagnosis and Undiagnosed Prevalence using a CD4-based Bayesian Back-calculation. Statistical Communications in Infectious Diseases, 2012, 4, .	0.2	5
78	Exploiting routinely collected severe case data to monitor and predict influenza outbreaks. BMC Public Health, 2018, 18, 790.	2.9	3
79	Nowcasting COVIDâ€19 deaths in England by age and region. Journal of the Royal Statistical Society Series C: Applied Statistics, 0, , .	1.0	2
80	Bayesian conditional-independence modeling of the AIDS epidemic in England and Wales. Physica D: Nonlinear Phenomena, 1999, 133, 145-151.	2.8	1
81	Evaluating the power of the causal impact method in observational studies of HCV treatment as prevention. Statistical Communications in Infectious Diseases, 2021, 13, .	0.2	1
82	Trends in outcomes following COVID-19 symptom onset in Milan: a cohort study. BMJ Open, 2022, 12, e054859.	1.9	1
83	P1-S4.26 Duration, incidence and prevalence of Chlamydia trachomatis in women: estimation by multi-parameter synthesis. Sexually Transmitted Infections, 2011, 87, A171-A171.	1.9	0